患有间歇性囊炎/膀疼痛综合征的患者的微生物群:系统性审查
Chaowei Fu1, Yuwei Zhang2, Linghui Liang3
1Wuxi School of Medicine, Jiangnan University, Wuxi, China.
BJU international
|June 18, 2024
概括
间歇性囊炎 (IC) /膀疼痛综合征 (BPS) 患者表现出明显的尿路微生物群变异,特别是乳酸菌的丰富性. 这表明失生症可能在IC/BPS中发挥作用,影响未来的诊断和治疗.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 间歇性囊炎 (IC) /膀疼痛综合征 (BPS) 是一种慢性疾病,病因不明.
- 微生物群在IC/BPS病原发生中的作用仍然是活跃的研究领域.
- 了解微生物差异可能会为新的诊断和治疗途径提供新的途径.
研究的目的:
- 系统地审查和评估关于IC/BPS患者与对照者的微生物群差异的文献.
- 为了确定特定的分类学和代谢变异.
- 提供潜在的临床实践指南.
主要方法:
- 在主要数据库 (PubMed,EMBASE,Web of Science,Cochrane) 进行系统的文献搜索.
- 包含/排除标准适用于12项选定的研究.
- 使用纽卡斯尔-太华尺度进行质量评估.
主要成果:
- 在IC/BPS患者中观察到尿路微生物群多样性和物种组成的显著变化.
- 发现了明显的细菌丰富度,特别是乳酸菌,以及代谢物变异.
- 在IC/BPS.中对肠道和阴道微生物群的分析有限.
结论:
- 证据支持与对照组相比,IC/BPS患者的尿道微生物群显著失调.
- 尿液微生物群的改变是IC/BPS的潜在病因因素.
- 这些发现对IC/BPS诊断和治疗有潜在的临床影响.
相关概念视频
Irritable Bowel Syndrome I: Introduction
268
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
268
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
156
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
156
Drugs for Treatment of Constipation-Predominant IBS
155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
Chronic Bowel Disorders: Introduction
440
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
440
Irritable Bowel Syndrome III: Medical and Nursing Management
194
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
194
Drugs for Treatment of Diarrhea-Predominant IBS
157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157


